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The sodium/iodide symporter (NIS) mediates a re-
markably effective targeted radioiodide therapy in
thyroid cancer; this approach is an emerging can-
didate for treating other cancers that express NIS,
whether endogenously or by exogenous gene
transfer. Thus far, the only extrathyroidal malig-
nancy known to express functional NIS endog-
enously is breast cancer. Therapeutic efficacy in
thyroid cancer requires that radioiodide uptake be
maximized in tumor cells by manipulating well-
known regulatory factors of NIS expression in thy-
roid cells, such as TSH, which stimulates NIS ex-
pression via cAMP. Similarly, therapeutic efficacy
in breast cancer will likely depend on manipulating
NIS regulation in mammary cells, which differs
from that in the thyroid. Human breast adenocar-
cinomaMCF-7 cells modestly express endogenous
NIS when treated with all-trans-retinoic acid (tRa).
We report here that hydrocortisone and ATP each
markedly stimulates tRa-induced NIS protein ex-
pression and plasma membrane targeting in
MCF-7 cells, leading to at least a 100% increase in
iodide uptake. Surprisingly, the adenyl cyclase ac-
tivator forskolin, which promotes NIS expression in
thyroid cells, markedly decreases tRa-induced NIS
protein expression in MCF-7 cells. Isobutylmethyl-
xanthine increases tRa-induced NIS expression in
MCF-7 cells, probably through a purinergic signal-
ing system independent of isobutylmethylxanthine’s
action as a phosphodiesterase inhibitor. We also
observed that neither iodide, which at high con-
centrations down-regulates NIS in the thyroid, nor
cAMP has a significant effect on NIS expression
in MCF-7 cells. Our findings may open new strat-
egies for breast-selective pharmacological mod-
ulation of functional NIS expression, thus im-
proving the feasibility of using radioiodide to
effectively treat breast cancer. (Molecular Endo-
crinology 20: 1121–1137, 2006)
A MAJOR DRAWBACK OF available traditionalcytotoxic anticancer therapies is that they are sig-
nificantly toxic to normal cells as well. Therefore, the
ultimate aim of any new anticancer therapy is to
achieve selective destruction of cancerous tissue with
minimal harm to healthy cells. One of the most prom-
ising approaches to accomplishing this goal is tar-
geted radiation therapy. In recent years, radionuclide-
bearing monoclonal antibodies (mAbs) have been
approved by the United States Federal Drug Admin-
istration, and several other antibodies (Abs) are cur-
rently on clinical trials. These mAbs bind to tumor-
specific antigens, thus selectively targeting cytotoxic
radionuclides to the tumor (1). Alternatively, cytotoxic
radionuclides can be specifically targeted by acting as
substrates of transport proteins that are selectively
expressed in tumoral tissue. These transport proteins
then translocate the radionuclides into tumoral cells
only.
The prime example of targeted radiation therapy via
a selectively expressed plasma membrane transporter
is radioiodide therapy. This is the most effective anti-
cancer targeted radiotherapy available today (2) and
has been employed for more than 60 yr to destroy
thyroid cancer remnants and/or metastases after thy-
roidectomy (3). The presence of the sodium/iodide
symporter (NIS) in thyroid cancer cells ensures that
administered radioiodide is selectively accumulated in
these cells, causing little damage to other cells and
only minimal side effects (2). Thus far, radioiodide
therapy has been viewed as applicable only to thyroid
cancer. Nevertheless, recent observations have raised
the possibility of applying radioiodide therapy to
breast cancer (4–6), and potentially to other cancers as
well, by introducing NIS into the tumor via viral vectors
(7–9) or up-regulating the tumors’ endogenous NIS
expression, if present (2, 4, 10, 11).
NIS was cloned in 1996 in our laboratory from the
highly functional rat thyroid-derived FRTL-5 cells (12).
It was subsequently demonstrated that the same NIS
protein mediates I transport in all tissues that con-
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Fig. 1. Hydrocortisone Increases tRa-induced Functional NIS Expression in MCF-7 Cells
A, Steady-state I uptake in MCF-7 cells: nontreated (white bar); treated for 48 h with 10 M hydrocortisone (H) (spotted bar),
1 M tRa (diagonally striped bar), or tRa and H combined (horizontally striped bar). Cells were incubated for 30 min with 20 M
Na125I and assayed as described in Materials and Methods. For comparison, I uptake in FRTL-5 cells is shown (gray bar). Black
bars represent NaClO4 (40 M) inhibition of I
 uptake in all cases. B, I efflux in MCF-7 cells treated with either tRa or tRaH is
similar and significantly slower than in FRTL-5 cells. Cells were incubated with 20 M Na125I for 30 min and washed; I efflux was
measured by replacing the HBSS solution every 10 min for 3 h and quantitating 125I. f, tRa-treated MCF-7 cells; F, tRaH-treated
MCF-7 cells; ‚, FRTL-5 cells. C and D, Hydrocortisone increases the Vmax of NIS-mediated I
 transport in tRa-treated MCF-7
cells without changing the Km of the transporter for either I
 (panel C) or Na (panel D). Initial rates (2-min time points) of I uptake
were determined at the indicated concentrations of I (as described inMaterials and Methods). Calculated curves were generated
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centrate I, including salivary glands, gastric mucosa,
and lactating mammary gland (4, 13, 14). Interestingly,
NIS is regulated differently in each of these tissues (4,
14, 15). Our secondary structure model for NIS pre-
dicts 13 transmembrane segments (16); we have ex-
perimentally demonstrated that the amino terminus
faces extracellularly and the carboxy terminus faces
intracellularly (17).
Driven by the Na gradient generated by the
Na/K ATPase, NIS couples the inward downhill
transport of Na down its concentration gradient to
the inward uphill translocation of I against its elec-
trochemical gradient. NIS transports 2 Na per each
I (18). Importantly, in addition to radioiodide, NIS also
transports other radionuclides with high therapeutic
potential, such as 188ReO4 (19) and
211At (20).
We have demonstrated in healthy mammary tissue
that NIS is expressed in lactating but not in nonlactat-
ing breast and have shown that NIS expression is
regulated by lactogenic hormones (4). By comparison,
in the thyroid NIS is expressed continuously and is
primarily regulated by TSH (14, 15, 17). We have ob-
served NIS-mediated I uptake in mammary adeno-
carcinomas in transgenic mice bearing ras or neu on-
cogenes and, even more significantly, we found NIS
expression in more than 80% of human breast cancers
by immunohistochemistry (4, 6, 21), whereas there
was no NIS expression in the surrounding noncancer-
ous breast tissue. In short, some regulatory mecha-
nisms cause NIS to be expressed only in lactating
breast and breast cancer but not in noncancerous
nonlactating breast. Furthermore, we have recently
demonstrated in vivo that NIS-mediated I uptake oc-
curs in human breast cancer metastases, and that
thyroidal I uptake can be selectively down-regulated
by administering thyroid hormones, which suppress
TSH production in the anterior hypophysis (6). This
would protect the thyroid from radioiodide adminis-
tered to destroy breast cancer cells. To reach maximal
therapeutic efficiency, patients with metastatic thyroid
disease are given a low iodide diet and recombinant
TSH (22). This greatly increases functional NIS expres-
sion and radioiodide accumulation in malignant thy-
roid tissue. Similarly, it is imperative to find compara-
ble ways to selectively induce or increase existing
endogenous functional NIS expression in breast can-
cer. Kogai et al. (11) have reported the induction of
functional NIS expression by all-trans-retinoic acid
(tRa) in the human adenocarcinoma-derived MCF-7
cell line. MCF-7 cells are an excellent and widely used
in vitro system for studying NIS regulation in human
breast cancer cells. Here we analyzed the effects of
hormones and other factors on NIS expression in
MCF-7 cells. We found that glucocorticoids and puri-
nergic regulatory mechanisms greatly enhanced tRa-
induced functional NIS expression in MCF-7 cells. In-
terestingly, factors that increased NIS expression in
MCF-7 cells have the opposite effect in FRTL-5 cells,
i.e. they down-regulate NIS expression. Our findings
open new strategies for carrying out selective phar-
macological modulation of radioiodide uptake in
breast cancer.
RESULTS
Hydrocortisone Increases tRa-Induced Iodide
Uptake in MCF-7 Cells
The combination of insulin, prolactin, and hydrocorti-
sone induces the synthesis of milk proteins such as
caseins and whey proteins in mammary epithelial cells
in vitro (23–25). Having shown in vivo that NIS is ex-
pressed in the breast exclusively during pregnancy
and lactation (4), we investigated whether lactogenic
hormones modulate NIS protein synthesis in MCF-7
cells. Given that insulin is a required factor in the
MCF-7 cell growth medium, we evaluated the effects
with the equation v  Vmax[I]/(Km[I]), using Gnuplot software. Cells were incubated for 2 min with the indicated concentrations
of Na; isotonicity was maintained constant with choline chloride. Na dependence data were analyzed with the equation
v  Vmax [Na
]2/Km[Na
]2). Data were fitted by nonlinear least squares using Gnuplot software. E, Total NIS protein expression
in nontreated, tRa-, or tRaH-treated (48 h) MCF-7 cells. Experiments were performed at least in triplicate; representative data are
shown. Upper panel, MCF-7 cells were treated for 48 h with 1 M tRa or with the combination of 1 M tRa and 10 M
hydrocortisone (panel H). Cells were lysed and subjected to immunoblot analysis with 4 nM anti-hNIS Ab. Total protein (20 g)
was loaded onto each lane. Middle panel, Equal loading was assessed by reprobing the same blot with an Ab against the
-subunit of the Na/K ATPase. Bottom panel, NIS protein expression was quantitated using ImageQuant software and
standardized for the loading control. F, Plasma membrane targeting of NIS in treated and nontreated MCF-7 cells. Upper panel,
Immunoblot analysis of biotinylated cell surface polypeptides using 4 nM anti-hNIS Ab was carried out as described in Materials
and Methods. Middle panel, Immunoblot analysis of biotinylated cell surface polypeptides, using an Ab against the -subunit of
the Na/K ATPase. Bottom panel, NIS plasma membrane localization was quantified by densitometry using ImageQuant
software and standardized for plasma membrane-localized -subunit of the Na/K ATPase. G–I, NIS expression analyzed by
indirect immunofluorescence. Lack of NIS expression in nontreated MCF-7 cells (panel G); intracellular and faint plasma
membrane-localized NIS expression in tRa-treated MCF-7 cells (panel H); clear plasma membrane localization of NIS in
tRaH-treated MCF-7 cells (panel I). Cells were incubated with 4 nM anti-hNIS Ab and subsequently with a fluorescent isothio-
cyanate-labeled antirabbit IgG (Vector laboratories) as described in Materials and Methods. J–L, Quantitation of NIS-expressing
MCF-7 cells before (panel J) and after treatment (48 h) with either tRa (panel K) or tRaH (panel L). Cells were probed first with 4
nM anti-hNIS Ab and subsequently with a fluorescent isothiocyanate-labeled anti-rabbit IgG. The fluorescence of 10,000 cells per
tube and percentage of NIS-expressing MCF-7 cells were determined by a FACScan flow cytometer (Becton Dickinson and Co.)
(see Materials and Methods for details).
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of hydrocortisone (10 M) and human recombinant
prolactin (10 ng/ml), either alone or in combination, on
steady-state I uptake. All experiments were per-
formed in the presence of 2.5% charcoal-treated fetal
bovine serum and 10 g/ml insulin; steady-state per-
chlorate-sensitive I uptake was measured 48 h after
each treatment. Neither hydrocortisone nor prolactin,
alone or together, induced I uptake in MCF-7 cells in
the absence of tRa (data not shown). However, hydro-
cortisone, when administered in combination with tRa
(tRaH), caused a 2-fold increase in I uptake (Fig. 1A,
horizontally striped bar) when compared with tRa
treatment alone (Fig. 1A, diagonally striped bar), lead-
ing to I accumulation levels comparable to those in
thyroid cells (Fig. 1A, gray bar). In contrast, prolactin,
even at doses as high as 100 ng/ml to 1g/ml, had no
effect on steady-state I uptake in cells simulta-
neously treated with either tRa alone or tRaH (data not
shown).
Steady-state I uptake is the result of I influx,
mediated by NIS, and I efflux, mediated by uniden-
tified channels or transporters. Hence, we measured
both I efflux and initial rates (2 min) of I uptake to
determine which of these two components is (or are)
modulated by hydrocortisone. For the efflux experi-
ments, cells were allowed to reach steady state; I
was then washed from the medium, thus causing in-
tracellular I to efflux as a result of the outwardly
directed I gradient. I efflux rates were exactly the
same in tRa- and tRaH-treated MCF-7 cells, although
these rates were considerably slower than those in
FRTL-5 cells (Fig. 1B). These findings indicate that
hydrocortisone increases tRa-induced I accumula-
tion in MCF-7 cells solely by increasing NIS-mediated
I transport, without affecting I efflux.
To further explore the effect of different hormonal
treatments on NIS function in MCF-7 cells, we per-
formed kinetic analyses of NIS-mediated I uptake
(Fig. 1, C and D). We measured the effect of varying
concentrations of I (ranging from 0.625 to 80 M) on
the initial rates (2 min) of I transport (Fig. 1C). In all
cases saturation was reached at an I concentration
of approximately 40 M. The apparent Vmax value of
NIS was significantly higher (2-fold) when the com-
bined tRaH treatment was used, as compared with tRa
alone [Vmax (ItRa)  4.5  0.1; Vmax (ItRaH)  9.2  0.4
pmol I/g DNA/2 min]. In contrast, the calculated
Michaelis-Menten constant (Km) values for I
 were
similar in both conditions [Km (ItRa)  7.5 1.2;
Km (ItRaH)  10.6  1.0 M]. We also investigated the
effect of varying concentrations of Na (ranging from
0–140 mM) on initial I uptake rates in MCF-7 cells
treated with either tRa or tRaH (Fig. 1D). Osmolarity
was kept constant with choline chloride. We found
that, similar to I, the Km of NIS for Na
 was the same
in cells subjected to either treatment [Km (Na-tRa) 
48.3  3.2, Km (Na-tRaH)  42.4  1.6 mM], whereas
the Vmax of Na
 transport was also increased 2-fold
[Vmax (Na-tRa)  3.0  0.1, Vmax (Na-tRaH)  6.1  0.1
pmol I/g DNA/2 min] when the combined treatment
was employed. These data suggest that the addition
of hydrocortisone to tRa results in the presence of
more functional NIS molecules in the plasma mem-
brane of MCF-7 cells.
The Combination of tRa and Hydrocortisone
Stimulates NIS Protein Expression and Targeting
to the Plasma Membrane
Having established that the combination of tRa and
hydrocortisone increases I uptake, we sought to dis-
cern the underlying mechanism involved. We as-
sessed NIS expression and its subcellular localization
in MCF-7 cells treated with either tRa alone or tRaH
(Fig. 1, E–I). When present, the NIS protein migrated as
an approximately 100-kDa mature and an approxi-
mately 60-kDa partially glycosylated polypeptide (17),
as determined by immunoblot analysis (Fig. 1E). We
found that both NIS protein expression and targeting
to the plasma membrane increased significantly in
cells treated with the tRaH combination compared
with those treated with tRa alone (Fig. 1, E–F). NIS
targeting to the plasma membrane was assessed by
surface biotinylation experiments carried out with the
amino-specific membrane-impermeable reagent
Sulfo-NHS-SS-biotin. The entire biotinylated fraction
was isolated with streptavidin-coated beads and im-
munoblotted with anti-hNIS Ab. Whereas an approxi-
mately 100-kDa immunoreactive band corresponding
to mature NIS was evident in the immunoblot, the
approximately 60-kDa partially glycosylated band was
not observed because it does not reach the plasma
membrane (Fig. 1F). Prolactin had no effect on NIS
protein expression, independently of whether it was
added alone or together with the tRaH combination
(data not shown).
The MCF-7 cell line is heterogeneous (26). Hence,
whereas NIS was clearly revealed by immunofluores-
cence to be localized in the plasma membrane of
tRaH-treated MCF-7 cells (Fig. 1I), not all cells ex-
pressed NIS. By flow cytometry [fluorescence-acti-
vated cell sorting (FACS)], we quantitated the percent-
age of cells expressing NIS after hormonal treatment
(Fig. 1, J–L), and observed that tRa induced NIS ex-
pression in only 10% of the cells (Fig. 1K). By com-
parison, the tRaH combination induced NIS expres-
sion in as many as 30% of the cells (Fig. 1L), indicating
that the addition of hydrocortisone led not only to
higher protein levels in tRa-responsive MCF-7 cells,
but also enhanced the stimulatory effect of tRa. Virtu-
ally identical results were obtained with two other Abs
directed against different NIS epitopes.
We determined the time course and dose depen-
dence of the hydrocortisone effect on tRa-induced I
uptake and NIS protein expression in MCF-7 cells (Fig.
2). The presence of 10 M hydrocortisone for more
than 12 h significantly increased I uptake (Fig. 2, A
and B), NIS protein expression (Fig. 2, C and D), and
plasma membrane targeting (Fig. 2, E and F). Incuba-
tion times up to 48 h resulted in no further increase in
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Fig. 2. Hydrocortisone Increases tRa-Induced NIS Expression in MCF-7 Cells in a Dose- and Time-Dependent Fashion
A, Steady-state I uptake in tRa-maintained (106 M) MCF-7 cells treated with increasing doses of hydrocortisone, or B, with 105
M hydrocortisone for the indicated times. For uptake measurements, cells were incubated in the presence of 20 M Na125I for 30 min
as described in Materials and Methods. C and D (upper panels), Immunoblot analysis of hNIS expression after hydrocortisone
administration at the indicated concentrations for 48 h; 20g of total protein were loaded per lane (panel C), and after the administration
of 10 M hydrocortisone for the indicated times; 10 g of total protein were loaded per lane (panel D).Middle panels, Loading control
(Na/K ATPase -subunit). Bottom panel, The relative expression levels of hNIS, compared with the housekeeping protein Na/K
ATPase -subunit, were quantified by densitometry using ImageQuant software. E–F (upper panels), Immunoblot analysis of biotin-
ylated cell surface polypeptides with anti-hNIS polyclonal Ab after hydrocortisone administration at the indicated concentrations for
48 h (panel E), and after the administration of 10 M hydrocortisone for various time lengths (panel F). Middle panels, loading control
(Na/K ATPase -subunit). Bottom panels, hNIS plasma membrane localization was quantified by densitometry using ImageQuant
software and standardized for plasma membrane-localized -subunit of the Na/K ATPase. H, Hydrocortisone.
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Fig. 3. IBMX Increases, whereas Forskolin Decreases Functional NIS Expression in tRaH-Treated MCF-7 Cells
A, Effect of 8-Br-cAMP and IBMX on steady-state I uptake in MCF-7 cells treated for 48 h with tRaH. Cells were incubated
for 30 min with 20 M Na125I and assayed as described in Materials and Methods. B, Total NIS protein expression in MCF-7 cells
after administration of tRaH plus 8-Br-cAMP and/or IBMX for 48 h. Upper panels, MCF-7 cells were treated for 48 h with the
combination of 1 M tRa and 10 M hydrocortisone (H) and with 100 M 8-Br-cAMP or 100 M IBMX, as indicated. Cells were
lysed and subjected to immunoblot analysis with 2 nM anti-hNIS Ab. Total protein (20 g) was loaded onto each lane. Middle
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NIS protein expression and I uptake (Fig. 2). In the
presence of tRaH, I uptake and NIS protein expres-
sion were maintained at a constant level, even after 6 d
of treatment (data not shown). In contrast to hydro-
cortisone, none of the other lactogenic hormones with
known roles in NIS regulation in mammary glands in
mice, namely oxytocin, prolactin, and estrogen, alone
or in combination, induced NIS expression or had any
effect on tRa- or tRaH-induced NIS expression or NIS
trafficking, or on I uptake in MCF-7 cells (data not
shown). Insulin or IGF-I treatment resulted in a slight
decrease of tRa- or tRaH-induced I uptake (data not
shown).
Isobutylmethylxanthine (IBMX), but not cAMP,
Stimulates I Uptake in tRa- and tRaH-Treated
MCF-7 Cells
The regulation of NIS by TSH in the thyroid is mediated
by cAMP (14, 15, 27, 28). Both the rat and human NIS
gene 5-untranslated regions contain a basic proximal
promoter and an upstream enhancer (NUE  NIS up-
stream enhancer) that recapitulates the most relevant
aspects of NIS regulation (28, 29). NUE, in turn, is
composed by a degenerate cAMP-responsive element
sequence flanked by two Pax8 binding sites. In the
thyroid, the binding of both Pax8 and an unidentified
cAMP-responsive element-like element binding factor
to NUE is required to obtain full TSH/cAMP-dependent
NIS transcription (28, 29). Given that cAMP plays a
central role in the regulation of thyroid NIS, we inves-
tigated the effect of cAMP on NIS expression in MCF-7
cells by adding 100 M 8-bromo-cAMP (8-Br-cAMP) (a
membrane-permeable cAMP analog) to untreated or
tRaH-treated MCF-7 cells. To slow down degradation
of cAMP, the phosphodiesterase inhibitor IBMX was
also added (100 M). Not only did cAMP have no
stimulatory effect but it had a slight inhibitory effect on
I uptake in treated (tRa or tRaH) cells (Fig. 3A). Sur-
prisingly, IBMX by itself caused a significant increase
(30%) of I uptake in both tRa- and tRaH-treated
MCF-7 cells (Fig. 3A). Immunoblot and surface bioti-
nylation experiments also showed that the tRaH-IBMX
treatment resulted in both higher overall NIS protein
expression and a higher number of NIS molecules in
the plasma membrane, as compared with tRaH-
treated cells (Fig. 3, B and C).
Kinetic analysis of I transport revealed that the
addition of IBMX to tRaH led to the presence of more
functionally active NIS molecules in the plasma mem-
brane of MCF-7 cells (Fig. 3, G and H). The Km values
of NIS for both I and Nawere very similar [Km (ItRaH)
 2.89  0.76 M; Km (ItRaH-IBMX)  5.1  1.16 M
Km (NatRaH)  41.7  7.5 mM; Km (NatRaH-IBMX) 
41.28  4.9 mM], whereas the Vmax values for both I

and Na increased significantly when IBMX was
added along with tRaH [Vmax (ItRaH)  2.67  0.14
pmol; Vmax (ItRaH-IBMX)  7.82  0.46 pmol;
Vmax (NatRaH)  3.44  0.28 pmol; Vmax (NatHRa-IBMX)
 5.98  0.34 pmol].
Although forskolin (20 M) (an adenyl cyclase ago-
nist) induces functional NIS expression in TSH-de-
prived FRTL-5 cells (27, 30), it significantly decreased
tRaH-induced NIS activity in MCF-7 cells, even after a
short administration (30 min) (Fig. 3D). These results
are different from the lack of effect of forskolin in
MCF-7 cells reported by Kogai et al. (10).
ATP Increases I Uptake in tRaH-Treated
MCF-7 Cells
That cAMP slightly decreased IBMX stimulation of
tRaH-induced I uptake and forskolin decreased
tRaH-induced I uptake suggested that the IBMX ef-
panels, Equal loading was assessed by reprobing the same blot with an Ab against the -subunit of the Na/K ATPase. Bottom
panel, NIS protein expression was quantitated using ImageQuant software and standardized for the loading control. C, Plasma
membrane targeting of NIS in MCF-7 cells treated as described in panel B. Upper panel, Immunoblot analysis of biotinylated cell
surface polypeptides, using 2 nM anti-hNIS Ab, carried out as described in Materials and Methods. Middle panel, Immunoblot
analysis of biotinylated cell surface polypeptides with an Ab against the -subunit of the Na/K ATPase. Bottom panel, NIS
plasma membrane localization was quantified by densitometry using ImageQuant software and standardized for plasma
membrane-localized -subunit of the Na/K ATPase. D, Steady-state I uptake of tRaH-treated MCF-7 cells after administration
of 20 M forskolin for the indicated times. Cells were incubated for 30 min with 20 M Na125I and assayed as described inMaterials
and Methods. E, Total NIS protein expression in MCF-7 cells in tRaH-treated MCF-7 cells after forskolin administration. Upper
panel, MCF-7 cells were treated for 48 h with tRaH plus 20 M forskolin for the indicated times. Middle panel, Equal loading was
assessed by reprobing the same blot with an Ab against the -subunit of the Na/K ATPase. Bottom panel, NIS protein
expression was quantitated using ImageQuant software and standardized for the loading control. F, Plasma membrane targeting
of NIS in tRaH- and forskolin-treated MCF-7 cells. Upper panels, Immunoblot analysis of biotinylated cell surface polypeptides
using 4 nM anti-hNIS Ab, carried out as described in Materials and Methods. Middle panel, Immunoblot analysis of biotinylated
cell surface polypeptides, using an Ab against the -subunit of the Na/K ATPase. Bottom panel, NIS plasma membrane
localization was quantified by densitometry using ImageQuant software and standardized for plasma membrane-localized
-subunit of the Na/K ATPase. G, IBMX significantly increases the Vmax of NIS-mediated I
 transport in tRaH-treated MCF-7
cells without changing the Km of the transporter for I
 or Na (panel H). Initial rates (2-min time points) of I uptake were
determined at the indicated concentrations of I as described inMaterials and Methods. Calculated curves were generated using
the equation v  Vmax[I]/(Km[I]) with Gnuplot software. H, To assess Na
 dependence of I uptake, cells were incubated for 2
min with the indicated concentrations of Na; isotonicity was maintained constant with choline chloride. Na dependence data
were analyzed using the equation v  Vmax [Na
]2/Km[Na
]2. Data were fitted by nonlinear least squares using the Gnuplot
software.
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Fig. 4. ATP Increases I Uptake in tRaH-Treated MCF-7 Cells in a Dose- and Time-Dependent Manner
A and B, Steady-state I uptake in tRaH-maintained MCF-7 cells treated with the indicated concentrations of ATP for 48 h
(panel A) or with 5 104 M ATP for the indicated times (panel B). Cells were incubated for 30 min with 20 M Na125I and assayed
as described in Materials and Methods. C and D, Total NIS protein expression in tRaH- and ATP-treated MCF-7 cells. Upper
panels, MCF-7 cells were treated with tRaH and with the indicated concentrations of ATP for 48 h (panel C), or with 5  104 M
ATP for the indicated times (panel D). Cells were lysed and subjected to immunoblot analysis using 2 nM anti-hNIS Ab. Total
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fect was independent of the intracellular levels of
cAMP. 8-Br-cGMP (up to 500 M) had no effect on
tRaH-induced I uptake in MCF-7 cells (data not
shown). Hence, the stimulatory effect of IBMX on I
transport may be related to the interaction of IBMX
with xanthine-sensitive purinergic P2 receptors (31).
When we administered ATP along with tRaH, we ob-
served a moderate but statistically significant increase
in NIS protein expression (Fig. 4, C and D) and plasma
membrane targeting (Fig. 4, E and F), consistent with
the increase in I uptake (Fig. 4, A and B). Maximal
effect was achieved by 500 M ATP administered for
more than 18 h (Fig. 4, A–F). ATP (500 M) adminis-
tered alone, without tRa or hydrocortisone, did not
induce functional NIS expression in MCF-7 cells (data
not shown). We measured initial rates of I uptake in
MCF-7 cells treated with tRaH and ATP and found a
similar increase in Vmax to the one observed in cells
treated with tRaH and IBMX (Fig. 4G).
To identify the purinergic receptor(s) involved in me-
diating ATP stimulation of I transport, we adminis-
tered nonhydrolyzable ATP analogs that exhibit differ-
ent affinities for various P2 receptors (32) (Fig. 5). All
experiments were carried out in tRaH-treated MFC-7
cells. The effect of administering IBMX and ATP to-
gether was indistinguishable from the effects of ad-
ministering IBMX or ATP alone (Fig. 5, A–C). Two ATP
analogs were tested, namely ATP--S, which interacts
with the P2Y1, P2Y2, P2Y11, and P2Y12 receptors,
and ADP--S, which interacts with the P2Y1, P2Y11,
and P2Y12 receptors. Whereas treatment with 100 M
ATP--S had a stimulatory effect similar to that of 500
M ATP, 100 M ADP--S had no effect (Fig. 5, A–C).
Because ATP--S binds with equally high affinity with
both P2Y1 and P2Y2, to determine which of these two
receptors was involved, we tested UTP, which inter-
acts with P2Y2 but not with P2Y1. We found that UTP
(100 or 500 M) modestly increased I uptake and NIS
protein expression (Fig. 5, D–F). This suggests that the
receptor involved is P2Y2.
To rule out the possibility that the ATP stimulation of
I transport was mediated by the ATP metabolite
adenosine rather than ATP itself, we tested the effect
of adenosine on I transport, by using stable adenosine
analogs exhibiting different affinities for the various
adenosine receptor subtypes. Neither N6-cyclopentyl-
adenosine, N-ethylcarboxamidoadenosine, nor N6-(3-
iodobenzyl)-9[5-(methylcarbamoyl--D-ribofuranosyl]-
adenine had any effect on tRa- or tRaH-induced
functional NIS expression in MCF-7 cells (data not
shown). In conclusion, given that a nonhydrolyzable
ATP analog mimicked the effect of ATP and adenosine
analogs had no effect, these data suggest that the
stimulatory effect of ATP on iodide transport is medi-
ated by the interaction of ATP with the purinergic
receptor P2Y2, not by adenosine interacting with
adenosine receptors.
NIS Regulation Differs Markedly in Thyroid vs.
Breast Cancer Cells
Functional NIS expression in FRTL-5 cells requires
TSH (10, 27), whereas in MCF-7 cells it requires tRa
(10). Interestingly, Schmutzler et al. (33) have reported
that 1 M tRa actually down-regulated NIS mRNA
levels and decreased I uptake in FRTL-5 cells, i.e.
tRa had the opposite effect on NIS in thyroid (FRTL-5)
cells compared with its effect in breast (MCF-7) cells.
Here we have shown, for the first time, that beyond its
effect on NIS mRNA and I uptake, tRa also de-
creased TSH-induced NIS protein expression and
plasma membrane targeting in FRTL-5 cells (Fig. 6,
A–C). Hydrocortisone, for its part, has been reported
to lower TSH-induced functional NIS expression in
thyroid cells (34), an observation we have confirmed
by measuring decreased TSH-induced steady-state I
uptake in FRTL-5 cells in response to hydrocortisone
treatment (data not shown). In contrast, we showed
that hydrocortisone markedly increased tRa-induced
I uptake in MCF-7 cells (Fig. 1). NIS expression in
thyroid and breast cancer cells is regulated by differ-
ent purinergic signals. The presence of multiple P2Y
receptor subtypes has been proven in FRTL-5 cells,
and these receptors have been suggested to partici-
pate in regulation of DNA synthesis (35, 36).
ATP increased NIS expression in MCF-7 cells (Figs.
4 and 5) probably via P2Y2 receptors. Surprisingly,
when we tested the effect of ATP on NIS expression in
FRTL-5 cells, we found that, in contrast to MCF-7
cells, ATP significantly reduced TSH-induced NIS pro-
tein expression, plasma membrane targeting, and
steady-state I uptake (Fig. 6, A–C). IBMX increased
I uptake both in FRTL-5 (30) and MCF-7 cells (Fig. 4),
probably by different mechanisms.
Other than TSH, I is the main regulator of NIS
expression and thus of its own transport in the thyroid.
protein (20 g) was loaded onto each lane. Middle panels, Equal loading was assessed by reprobing the same blot with an Ab
against the -subunit of the Na/K ATPase. Bottom panel, NIS protein expression was quantitated using ImageQuant software
and standardized for the loading control. E and F, Plasma membrane targeting of NIS in MCF-7 cells treated with tRaH and with
the indicated concentrations of ATP for 48 h (panel E), or with 5  104 M ATP for the indicated times (panel F). Upper panel,
Immunoblot analysis of biotinylated cell surface polypeptides using 2 nM anti-hNIS Ab, carried out as described in Materials and
Methods. Middle panel, Immunoblot analysis of biotinylated cell surface polypeptides using an Ab against the -subunit of the
Na/K ATPase. Bottom panel, NIS plasma membrane localization was quantified by densitometry using ImageQuant software
and standardized for plasma membrane-localized -subunit of the Na/K ATPase. G, IBMX and ATP increase to a similar extent
the Vmax of NIS-mediated I
 transport in tRaH-treated MCF-7 cells, without changing the Km of the transporter for I
. Initial rates
(2-min time points) of I uptake were determined at the indicated concentrations of I as described in Materials and Methods.
Calculated curves (smooth lines) were generated using the equation v  Vmax[I]/(Km[I]) with Gnuplot software.
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Fig. 5. Effect of Various P2 Receptor-Specific Ligands on tRaH-Induced I Uptake in MCF-7 Cells
A and D, Steady-state I uptake of MCF-7 cells treated 48 h with 100 M ATP--S (a P2Y1, P2Y2, P2Y11, and P2Y12 agonist)
increased tRaH-induced steady-state I uptake of MCF-7 cells to an extent similar to that of ATP (500 M) or IBMX (100 M); in
contrast, ADP--S (a P2Y1, P2Y11, and P2Y12 agonist) exhibited no effect (panel A). UTP (a P2Y2 agonist) only moderately
increased tRaH-induced steady-state I uptake in MCF-7 cells. All cells were treated with tRaH; only ATP, IBMX, ATP--S,
ADP--S (panel A), and UTP (panel D) treatments are indicated. Cells were incubated for 30 min with 20 M Na125I and assayed
as described inMaterials and Methods. B and E, Total NIS expression in tRaH-treated MCF-7 cells after administration of various
P2 receptor ligands. Upper panels, MCF-7 cells were treated for 48 h with tRaH and either ATP (500 M), IBMX (100 M), ATP--S
(100 M), ADP--S (100 M), or UTP (100 and 500 M) for 48 h, as indicated. Cells were lysed and subjected to immunoblot
analysis with 4 nM anti-hNIS Ab. Total protein (20 g) was loaded onto each lane. Middle panels, Equal loading was assessed by
reprobing the same blot with an Ab against the -subunit of the Na/K ATPase. Bottom panels, NIS protein expression was
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The Wolff-Chaikoff effect, first described in 1948, is
the blocking of thyroid I organification (covalent in-
corporation of I into thyroglobulin) by high concen-
trations of I itself (37). Shortly after this condition is
established, the thyroid gland protects itself against I
overload by down-regulating the transport of the an-
ion, leading to restoration of I organification. This
latter physiological phenomenon is called the “es-
cape” from the acute Wolff-Chaikoff effect (38, 39).
With the availability of the NIS cDNA and NIS Abs, it
was shown that high I doses down-regulate NIS pro-
tein expression, and consequently I transport, mostly
by a posttranslational mechanism that remains to be
fully characterized (39–42). To examine whether I
modulates NIS activity in breast epithelial cells,
FRTL-5 and MCF-7 cells were incubated with 100 M
Na125I overnight, and then assayed for I transport
and NIS protein expression. Surprisingly, I preincu-
bation had no effect either on I transport or NIS
protein expression in MCF-7 cells (Fig. 6, D–F, right
panels). This contrasted both with the expected and
previously reported (39–42) inhibition of I uptake by
I preincubation in thyroid cells (Fig. 6D, left panel),
and with the presently observed decrease in expres-
sion at the plasma membrane by I preincubation (Fig.
6F, left panel), an effect that had not been shown
before.
DISCUSSION
NIS-mediated radioiodide treatment of metastatic thy-
roid cancer after thyroidectomy is the most effective
anticancer targeted radiotherapy available today, and
it causes only minimal side effects (2). Breast cancer is
the only malignancy other than thyroid cancer to have
been shown thus far to exhibit endogenous functional
NIS expression, not only in primary tumors but also in
metastases (4–6). Given the enormous health impact
of breast cancer (200,000 newly diagnosed cases
per year in the United States), endogenous NIS ex-
pression is a distinct advantage of this disease over
other malignancies for the purpose of treating it with
radioiodide therapy, because it is a cancer that only
requires optimization of its existing intrinsic NIS activ-
ity without the need to introduce NIS into tumor cells
by means of gene transfer techniques (4–6).
An understanding of NIS regulation is a key require-
ment for optimizing radioiodide therapy in breast can-
cer, as has been done in thyroid cancer. Therefore, we
have investigated the regulation of NIS activity by a
variety of factors in MCF-7 cells, a frequently used in
vitro model system to study regulatory effects in hu-
man breast adenocarcinoma, and observed that NIS
regulation in these cells is markedly different from that
in thyroid FRTL-5 cells. Kogai et al. (10, 43) have
demonstrated that tRa (or some tRA analogs, like
9-cis-retinoic acid and AGN190168) is an absolute
requirement to induce NIS expression in MCF-7 cells,
an observation that we have confirmed in this study. In
contrast, Arturi et al. (44) reported that iodide uptake in
MCF-7 cells could be induced by insulin, IGF-I, IGF-II,
and prolactin in the absence of tRa, a finding that we
could not reproduce either under serum-starved or
nonstarved conditions. Moreover, when we added
these growth factors simultaneously with tRa or tRaH,
insulin or IGF-I actually had a slight inhibitory effect
(data not shown).
Being convinced that tRa treatment is an absolute
requirement to elicit NIS expression in MCF-7 cells, we
sought to test modulators that might increase the tRa
effect, such as hydrocortisone, a hormone that in-
duces milk protein synthesis in cell and organ cultures
when given in combination with insulin and prolactin
(23–25). Indeed, we found that hydrocortisone signif-
icantly enhanced tRa-induced I transport in MCF-7
cells (Fig. 1A). In a time- and dose-dependent fashion,
hydrocortisone increased the Vmax (Fig. 1, C and D) of
tRa-induced I transport in MCF-7cells by increasing
total (Fig. 1E) and cell surface NIS protein expression
(Fig. 1F), without affecting I efflux (Fig. 1B). Hydro-
cortisone alone (i.e. without tRa) did not have a signif-
icant effect (Fig. 1A). Our observations confirm and
extend those from a recent report by Kogai et al. (43)
showing that dexamethasone increased tRa-induced
I uptake in MCF-7 cells. These authors suggested
that hydrocortisone stabilizes tRa-induced NIS mRNA
(43). Future studies are necessary to elucidate the
mechanism of the tRa-hydrocortisone effect.
MCF-7 cells are known to be heterogenous (26).
When treated with tRa, only 10% of cells exhibited NIS
expression (Fig. 1K). In contrast, when cells were
treated with the tRaH combination, as many as 30% of
the cells expressed NIS protein (Fig. 1L). This clearly
indicates that hydrocortisone significantly enhances
the turn-on effect of tRa on NIS expression. Not much
is known about the mechanism by which tRa up-
regulates NIS expression in MCF-7 cells. Recently,
Dentice et al. (45) observed that, in MCF-7 cells, tRa
treatment induces the expression of Nkx-2.5, a car-
diac homeobox transcription factor that, in turn, is a
potent inducer of the NIS promoter.
quantitated using ImageQuant software and standardized for the loading control. C and F, Plasma membrane targeting of NIS
in tRaH- and P2 receptor agonist-treated MCF-7 cells. Upper panels, Immunoblot analysis of biotinylated cell surface polypep-
tides using 4 nM anti-hNIS Ab, carried out as described in Materials and Methods. Middle panels, Immunoblot analysis of
biotinylated cell surface polypeptides using an Ab against the -subunit of the Na/K ATPase. Bottom panels, NIS plasma
membrane localization was quantified by densitometry using ImageQuant software and standardized for plasma membrane-
localized -subunit of the Na/K ATPase.
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Fig. 6. NIS Regulation Differs Markedly in MCF-7 and FRTL-5 Cells
A, Steady-state I uptake is reduced in FRTL-5 cells upon addition of TSH combined with either 500 M ATP or 1 M tRa. FRTL-5 cells
were kept for 6 dwithout TSH; TSHwas then added either with ATP or tRa for 48 h. B, Both ATP and tRa decrease TSH-inducedNIS protein
expression in FRTL-5 cells.Upper panel, Immunoblot analysis of rNISexpression (20g total protein/lane) in FRTL-5 cells kept in the absence
of TSH for 6 d; TSH was added in combination with either ATP or tRa for 48 h.Middle panel, Loading control (tubulin). Bottom panel, NIS
protein expression was quantitated using ImageQuant software and standardized for the loading control. C, Plasmamembrane targeting of
NIS in FRTL-5 cells after TSH induction and treatment with ATP or tRa using anti-rNIS polyclonal Ab. Upper panels, Immunoblot analysis of
biotinylated cell surface polypeptides using 4 nM anti-rNIS Ab, carried out as described inMaterials andMethods. Middle panel, Immunoblot
analysis of biotinylated cell surface polypeptides using an Ab against the -subunit of the Na/K ATPase. Bottom panel, NIS plasma
membrane localization was quantified by densitometry using ImageQuant software and standardized for plasma membrane-localized
-subunit of the Na/K ATPase. D, Steady-state I uptake in FRTL-5 andMCF-7 cells after preincubationwith 100MNa125I. FRTL-5 cells
were incubated for 6 h andMCF-7 cells were incubated for 12 h in media containing 100 M Na125I overnight or for 30 min; accumulated I
was determined as described in Materials and Methods. E, Total NIS protein expression in FRTL-5 and MCF-7 cells after 100 M NaI
treatment.Upper panel, Immunoblot analysis of NIS expression (20g total protein/lane) in FRTL-5 andMCF-7 cells treatedwith 100MNaI
for 6 or 12 h, respectively.Middle panel, Loading control (FRTL-5 cells, tubulin;MCF-7 cells,-subunit of theNa/KATPase).Bottompanel,
NIS protein expressionwas quantitated using ImageQuant software and standardized for the loading control. F, Plasmamembrane targeting
of NIS in FRTL-5- and tRaH-treated MCF-7 cells after administration of 100 M NaI. Upper panel, Immunoblot analysis of biotinylated cell
surface polypeptides using 2 nM anti-hNIS Ab or anti-rNIS Ab, carried out as described inMaterials andMethods. Middle panel, Immunoblot
analysis of biotinylated cell surface polypeptides using an Ab against the -subunit of the Na/K ATPase. Bottom panel, NIS plasma
membrane localization was quantitated by densitometry using ImageQuant software and standardized for plasma membrane localized
-subunit of the Na/K ATPase. Contr, Control.
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In the thyroid, a major modulator that markedly up-
regulates NIS expression is cAMP (27–29). Hence, we
tested 8-Br cAMP, a membrane-permeable analog of
cAMP; forskolin, an adenyl cyclase activator; and
IBMX, a phosphodiesterase inhibitor in MCF-7 cells.
All three lead to increased intracellular cAMP levels.
Interestingly, far from stimulating it, 8-Br-cAMP
caused a very slight decrease in both tRa- and tRaH-
induced I uptake. This finding alone indicates that
cAMP does not play the same up-regulating role in NIS
expression in breast cancer cells as it does in thyroid
cells (15, 27). Kogai et al. (10) reported no effect of
forskolin alone (i.e. without tRa) on NIS expression in
MCF-7 cells, an observation we have confirmed (data
not shown), demonstrating that, in the absence of tRa,
cAMP alone does not up-regulate NIS in these cells.
Like 8-Br-cAMP, forskolin also caused a decrease in
both tRa- and tRaH-induced I uptake in MCF-7 cells
(Fig. 3D), although the decrease was much more pro-
nounced than that with 8-Br-cAMP, and most likely
was not due to higher intracellular cAMP levels. In
stark contrast, Arturi et al. (44) reported that forskolin
and dibutyryl-cAMP treatment produced a minimal in-
crease of I uptake in MCF-7 cells.
Given that both 8-Br-cAMP and forskolin caused a
decrease in both tRa- and tRaH-induced NIS activity,
it was most surprising to find that IBMX significantly
increased, rather than decreased, I uptake (both ini-
tial rates and steady state) and NIS protein expression
in these cells (Fig. 3), an effect that was clearly inde-
pendent of phosphodiesterase inhibition and of cAMP
levels.
Although the above observations appear to be in
conflict with a report by Knostman et al. (46) stating
that cAMP induces NIS expression in breast cancer,
there is no real discrepancy with our findings: these
authors observed that 8-Br-cAMP treatment stimu-
lated NIS mRNA expression in MCF-7 cells, but there
was no concomitant increase in I uptake. Like Kogai
et al. (10) and our group, Knostman et al. (46) also
found that forskolin alone did not increase I uptake in
MCF-7 cells. Thus, in light of our current findings, we
conclude that cAMP does not induce NIS protein ex-
pression and function in MCF-7 cells. In contrast,
IBMX up-regulates both I uptake and NIS protein
expression in these cells, albeit by a mechanism that
does not involve either phosphodiesterase inhibition
or an increase in intracellular cAMP levels. Therefore,
we suggest that the up-regulating effect of IBMX on
NIS expression in MCF-7 cells, also reported by
Knostman et al., is unrelated to cAMP.
Having ruled out the possibility that the surprising
non-cAMP-dependent stimulatory effect of IBMX on
NIS expression was mediated by an increase in cGMP
(data not shown), and considering that the effect was
clearly not mediated by phosphodiesterase inhibition,
we analyzed the potential involvement of purinergic
signaling. Methylxanthines are known antagonists of
adenosine receptors, and the possible existence of
methylxanthine-sensitive purinergic receptors has
also been described (31). We found that ATP, like
IBMX, significantly increased tRaH-induced I uptake
in MCF-7 cells. A given epithelial cell type commonly
expresses a mixture of various purinergic receptors,
and the combination of the different receptors that are
present determines how the signal is transduced from
the extracellularly released ATP and/or its metabolites.
Purinergic receptors are divided into two classes: G
protein-coupled P1 adenosine receptors and nucleo-
tide P2 receptors, which bind ATP, ADP, UTP, and
UDP. Yoshioka et al. (47) have recently reported that
the A1 and P2Y1 receptors can oligomerize, thus re-
sulting in A1 receptor ligand-induced P2Y1 receptor
signaling. In addition to the versatility of receptors
capable of transmitting purinergic signals, other fac-
tors influencing their signaling are the metastable na-
ture of ATP and the role of its metabolites. Extracel-
lularly, ATP is degraded rapidly by different ecto-
enzymes, yielding ADP, 5-AMP, and adenosine. We
observed no effect of stable adenosine analogs on
tRaH-induced I uptake (data not shown), ruling out
the possibility that IBMX acts through adenosine re-
ceptors or that the effect of ATP is mediated by its
metabolite adenosine.
The complex interactions described above make it
difficult to identify with certainty the purinergic recep-
tor that mediates the stimulation of NIS expression by
ATP. Still, we addressed this point by administering
various ATP analogs and other nucleotides with dif-
ferent receptor specificities and determining their ef-
fectiveness in stimulating I transport in MCF-7 cells
(Fig. 5). ATP and UTP are known to elevate intracellular
calcium and stimulate proliferation via activation of the
P2Y2 receptor in MCF-7 cells. These cells express
P2Y2 receptors and proliferate in response to both
ATP and UTP (48). We found that the nonhydrolyzable
ATP analog ATPS was as effective as ATP itself in
stimulating I transport, whereas UTP was noticeably
less so and ADPS had no effect (Fig. 5). These find-
ings suggest that the receptor involved is probably
P2Y2 (32).
We have previously reported that functional NIS ex-
pression in the mammary gland appears during the
second half of gestation and is maintained thereafter
by suckling during lactation (4). We have also shown
that, whereas oxytocin alone up-regulates NIS expres-
sion in the mammary glands of nubile mice, the com-
bination of estrogen, oxytocin, and prolactin induces
the highest NIS protein expression (4). The lack of any
effect of prolactin and oxytocin on NIS expression in
MCF-7 cells (data not shown) could be explained ei-
ther by the malignant status of these cells or by the
absence of the required microenvironment, particu-
larly myoepithelial cells. Furthermore, it has been ob-
served that tRa down-regulates prolactin receptor ex-
pression in MCF-7 cells (49). In these cells, ATP and
UTP promote cell proliferation via stimulation of the
P2Y2 receptors (48, 50). In the lactating mammary
gland, P2Y2-expressing secretory epithelial and
P2Y1-expressing myoepithelial cells are believed to
Doha´n et al. • Regulation of NIS-Mediated Iodide Uptake Mol Endocrinol, May 2006, 20(5):1121–1137 1133
interact via released ATP to enhance milk ejection
(51–53). Mechanical stretch (e.g. alveoli filling with
milk) induces ATP release from epithelial cells (51–53).
Oxytocin, which by itself is able to up-regulate NIS
expression in nubile mice, most likely exerts its effect
through the myoepithelial cells. Myoepithelial cell con-
traction in response to oxytocin leads to ATP release,
which probably increases NIS expression and I
transport into the epithelial cells. Our study of the
purinergic regulation of NIS expression, reported here
for the first time, shows that ATP up-regulates NIS
expression in MCF-7 cells (Fig. 4) but decreases it in
FRTL-5 cells (Fig. 6, A–C). The main requirement for
NIS expression in FRTL-5 cells is TSH, whereas in
MCF-7 cells it is tRa. TSH has no effect in MCF-7 cells.
In FRTL-5 cells, cAMP is the main positive regulator of
NIS expression, but in MCF-7 cells, cAMP had no
effect on NIS expression (Fig. 3, A–C). Clearly, the
regulation of NIS expression is tissue specific, and
some regulatory factors have opposite effects on NIS
expression in different tissues. tRa significantly de-
creased the amount of total and plasma membrane-
localized NIS protein in FRTL-5 cells (Fig. 6, A–C); in
contrast, tRa had the opposite effect in MCF-7 cells
(Fig. 1). Hydrocortisone, which is added to the FRTL-5
media to improve surface attachment (34), decreases
TSH-induced I uptake in FRTL-5 cells, whereas it
significantly enhanced tRa-induced NIS expression in
MCF-7 cells (Fig. 1). It has long been known that I at
high concentrations down-regulates its own transport
in thyroid cells. Here we have shown, for the first time,
that I, even at high concentrations, had no effect on
its own transport in MCF-7 cells (Fig. 6).
In conclusion, having previously reported NIS pro-
tein expression in more than 80% of human breast
cancers (4) and functional NIS expression in human
breast cancer metastases in vivo (6) without expres-
sion in healthy nonlactating mammary tissue (4), we
have now demonstrated that: 1) hydrocortisone and
ATP stimulate tRa-induced functional NIS expression
in human breast carcinoma MCF-7 cells; 2) IBMX in-
creases tRa-induced NIS expression in these cells by
a purinergic signaling pathway; and 3) regulatory fac-
tors of NIS expression exert different and sometimes
even opposite effects on breast cancer as compared
with thyroid cells. The differences in regulatory mech-
anisms of NIS expression between these tissues pro-
vide a key advantage for the development of selective
treatment strategies that would destroy breast cancer
cells without harming the thyroid. As MCF-7 and
FRTL-5 cells have been extensively used for in vitro
investigations of in vivo regulatory processes of breast
cancer and healthy thyroid, respectively, data ob-
tained in these cell lines are widely regarded as being
potentially physiologically relevant. Thus, our results
may be a significant step toward the goal of effectively
applying radioiodide in the diagnosis and therapy of
breast cancer. Nevertheless, these findings on selec-
tive up-regulation of NIS expression in breast cancer
cells by tRa, hydrocortisone, and IBMX will require
subsequent in vivo validation in future animal and,
eventually, human studies.
MATERIALS AND METHODS
Materials
All-trans-retinoic acid, hydrocortisone, 8-Br-cAMP, 8-bromo-
guanosine-3,5-cyclomonophosphate sodium salt (8-bro-
mo-cGMP), IBMX, ATP, ATP--S, ADP--S, UTP, adenosine,
N6-cyclopentyladenosine, N6-(3-iodobenzyl)-9[5-(methylcar-
bamoyl--D-ribofuranosyl]adenine, N-ethylcarboxamidoad-
enosine, estradiol, human recombinant prolactin, and oxyto-
cin were from Sigma-Aldrich (St. Louis, MO). Forskolin was
from Calbiochem (San Diego, CA).
Cell Culture
MCF-7 cells (lot 2188915) were purchased from American
Type Culture Collection (Manassas, VA), and they were
grown in Eagle’s MEM with Earle’s balanced salt solution and
2 mM L-glutamine, containing 1 mM sodium pyruvate, 0.1 mM
nonessential amino acids, 1.5 g/liter sodium bicarbonate, and
supplemented with 0.01 mg/ml bovine insulin and 10% fetal
bovine serum. Before (48 h) and during the hormonal treat-
ments, the medium was switched to medium containing only
2.5% charcoal dextran-stripped serum (Gemini Bio-Prod-
ucts, Woodland, CA). FRTL-5 cells were maintained as de-
scribed previously (15).
Iodide Uptake
After the culture medium was aspirated, cells were washed
twice with 1 ml of a modified Hanks’ balanced salt solution
(buffered HBSS) with the following composition: 137 mM
NaCl, 5.4 mM KCl, 1.3 mM CaCl2, 0.4 mM MgSO4  7 H2O, 0.5
mM MgCl2, 0.4 mM Na2HPO4  7 H2O, 0.44 mM KH2PO4, and
5.55 mM glucose with 10 mM HEPES buffer (pH 7.3). Cells
grown in 24-well plates were incubated with buffered HBSS
containing 20 M NaI supplemented with 10 Ci/l carrier-
free Na125I to give a specific activity of 100 mCi/mmol. For
steady-state experiments, incubations proceeded at 37 C for
45 min in a humidified atmosphere and were terminated by
aspirating the radioactive medium and washing twice with 1
ml ice-cold HBSS. For kinetic analysis, cells were incubated
for 2 min with 0.625, 1.25, 2.5, 5, 10, 20, 40, or 80 M NaI, and
uptake reactions were terminated as indicated above. Data
were processed using the equation: v  Vmax  [I]/(Km[I]). To
assess Na dependence of I uptake, cells were incubated
for 2 min with 0, 5, 10, 20, 30, 40, 80, or 140 mM NaCl;
isotonicity was maintained constant with choline Cl. Na
dependence data were analyzed using the equation: v 
Vmax  [Na
] 2/Km[Na
]2. Data were fitted by nonlinear least
squares using Gnuplot software (www.gnuplot.info). Nonspe-
cific background, as measured in nontreated cells, was
subtracted.
To determine the amount of 125I accumulated in the cells,
500 l 95% ethanol was added to each well for 20 min at 4
C and then quantitated in a -counter. The DNA content of
each well was determined on the material not extracted by
ethanol after trichloroacetic acid precipitation, by the diphe-
nylamine method, as previously described (54). I uptake
was expressed as picomoles per g DNA. All parameters
were determined at least in triplicate.
Immunoblot Analysis of Total and Biotinylated Plasma
Membrane Proteins
Cells were grown in six-well plates to 80% confluence. Cells
were rinsed at 4 C twice with PBS/Ca2/Mg2 (138 mM NaCl;
1134 Mol Endocrinol, May 2006, 20(5):1121–1137 Doha´n et al. • Regulation of NIS-Mediated Iodide Uptake
2.7 mM KCl; 1.5 mM KH2PO4; 9.6 mM Na2HPO4; 1 mM MgCl2;
0.1 mM CaCl2, pH 7.4). Cells were next incubated with 500
l/well of a solution containing 1.5 mg/ml sulfo-NH-SS-biotin
(Pierce Chemical Co., Rockford, IL) in biotinylation buffer
[HEPES 20 mM (pH 8.5), CaCl2 2 mM, NaCl 150 mM] for 20 min
at 4 C with gentle shaking. The biotinylation solution was
removed by two washes in PBS Ca2/Mg2 containing 100
mM glycine. Cells were lysed with 1 ml of lysis buffer (50 mM
Tris-HCl, pH 7.5; 150 mM NaCl; 5 mM EDTA; 1% Triton X-100;
1% sodium dodecyl sulfate; protease inhibitors) at 4 C for 15
min. A 200-l aliquot was taken for assessing total NIS ex-
pression by immunoblot. The remaining cell lysate (800 l)
was incubated overnight at 4 C with 50 l of streptoavidin
agarose beads (Pierce). Beads were centrifuged at 5000  g
for 2 min and rinsed three times with lysis buffer, twice with
high-salt, and once with low-salt solution. Adsorbed proteins
were eluted from the beads with sample buffer containing 10
mM dithiothreitol, at 75 C for 5 min, and analyzed by immu-
noblot. Ab purification was performed as described previ-
ously (17).
PAGE and electroblotting to nitrocellulose were performed
as previously described (17). Immunoblot analysis was also
carried out as described (17), with affinity-purified 4 nM anti-
human NIS or 4 nM antirat NIS Ab, and a 1:2000 dilution of a
horseradish peroxidase-linked donkey antirabbit IgG (Chemi-
con, Temecula, CA). Both incubations were performed for
1 h. Proteins were visualized by the enhanced chemilumines-
cence Western blot detection system (Amersham Pharmacia
Biotech, Arlington Heights, IL). Equal loading was assessed
by reprobing the same blot with a mAb against the -subunit
of the Na/K ATPase (Affinity BioReagents, Inc., Golden,
CO). Protein expression was quantitated using ImageQuant
software (Molecular Dynamics, Inc., Sunnyvale, CA) and
standardized for the loading control.
Immunofluorescence Analysis
MCF-7 cells were seeded onto polylysine-coated cover slips.
They were fixed with 2% paraformaldehyde for 30 min at
room temperature and then rinsed with PBS containing 0.1
mM CaCl2 and 1 mM MgCl2, subsequently referred to as
PBS-C-M. Cells were permeabilized with PBS-C-M-0.2%
BSA-0.1% Triton for 10 min and then quenched with 50 mM
NH4Cl in PBS-C-M for 10 min. Cells were rinsed with PBS-
C-M-BSA-Triton and incubated for 1 h at room temperature
with 4 nM affinity-purified anti-hNIS Ab in PBS-C-M-BSA-
Triton. Subsequently, cells were washed three times for 10
min with PBS-C-M-BSA-Triton, incubated for 1 h in the dark
with antirabbit fluorescein-conjugated secondary Ab (Vector
Laboratories, Inc., Burlingame, CA) (1:1000 dilution), and
washed as above. Cover slips were mounted onto slides with
Slow Fade antifade reagent (Molecular Probes, Inc., Eugene,
OR), sealed with quick-dry nail polish, and allowed to dry in
the dark for 2 h at room temperature and then stored at 4 C
in the dark. Cells were visualized in a Bio-Rad Radiance 2000
Laser Scanning Confocal Microscope (Bio-Rad Laboratories,
Inc., Hercules, CA).
Flow Cytometry
MCF-7 cells were detached with trypsin, counted, fixed in
PBS containing 2% paraformaldehyde, and then permeabil-
ized with 0.2% saponin in PBS supplemented with 0.1% BSA
and transferred into 5-ml polystyrene tubes (200,000 cells per
tube). Cells were incubated for 1 h at room temperature with
100 l PBS-0.1% BSA-0.2% Sap containing 4 nM anti-hNIS
Ab. Cells were washed with 1 ml PBS-BSA-saponin and
centrifuged as above. Next, they were incubated for 30 min at
room temperature in the dark with fluorescein-conjugated
antirabbit IgG (Vector Laboratories) at a 1:1000 dilution in the
same buffer. Cells were washed once again, centrifuged, and
resuspended in 300 l PBS. The fluorescence of 10,000 cells
per tube was assayed by a FACScan flow cytometer (Becton
Dickinson and Co., Franklin Lakes, NJ).
Statistical Analysis
Statistical analyses were performed using Student’s t test.
Each experimental condition was compared with its respec-
tive control group; P values below 0.05, below 0.01, and
below 0.001 are represented as *, **, and ***, respectively, in
all figures.
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